The FDA's Office of Prescription Drug Promotion is restructuring its professional and consumer marketing review divisions to provide tight supervision of direct-to-consumer advertising. The changes, which include organizing oversight by therapeutic class instead of target audience, will help achieve the goals of removing redundancy, enhancing work distribution and increasing efficiency, Center for Drug Evaluation and Research Director Dr. Janet Woodcock wrote in an e-mail.

Full Story:

Related Summaries